Antibodies Binding Axl
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2015/065900, filed Jul 10, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,201,607 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 10,500,276 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 10,512,688 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 10,765,743 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 12,589,150 | Antibodies Binding Axl In force · Medium confidence | Genmab A/S | In force | Medium confidence | ||
| Application 16/673,383 | Antibodies Binding Axl Abandoned Abandoned Mar 7, 2023 | Genmab A/S | Abandoned | Abandoned Mar 7, 2023 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Genmab A/S.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.